comparemela.com

Latest Breaking News On - Brad rovin - Page 1 : comparemela.com

Sparsentan Limits eGFR Reduction Regardless of IgAN Patient Proteinuria Levels

Sparsentan Limits eGFR Reduction Regardless of IgAN Patient Proteinuria Levels
hcplive.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from hcplive.com Daily Mail and Mail on Sunday newspapers.

Brad-rovin
National-kidney-foundation
Ohio-state-university-wexner-medical-center
Clinical-meeting
Long-beach
Travere-therapeutics-supported

Advancing Lupus Care: The Changing Landscape of Treatment

The progression toward more targeted, disease-modifying options for the historically difficult rheumatic disease made more headway in 2023.

Massachusetts
United-states
Aprilm-jorge
Brad-rovin
Jack-arnold
Rosalind-ramsey-goldman
Chris-wincup
European-alliance-of-associations
Ohio-state-university-wexner-medical-center
Drug-administration
King-college-hospital-lupus-unit
Leeds-centre-of-rheumatic

Use of Povetacicept in Treatment of IgA Nephropathy

Drs Jonathan Barratt and Brad Rovin comment on clinical trial data regarding the use of povetacicept for the treatment of IgAN.

United-states
American
Brad-rovin
Jonathan-barratt
American-society-of-nephrology
American-society
Povetacicept
Wigan
Nephropathy
Proteinuria
Complement-inhibition
B-cell-modulation

The Future of IgA Nephropathy Treatment

Jonathan Barratt, PhD, FRCP, and Brad Rovin, MD, discuss the future of IgAN treatment, highlighting the BlyS/APRIL axis.

Brad-rovin
Jonathan-barratt
Future-considerations
Wigan
Phase-3-clinical-trial-data
April
Blys-april
Povitacicept
Kdigo

Dual Inhibition of BlyS and APRIL in IgA Nephropathy

Nephrology experts explore the role of dual inhibition of BlyS and APRIL in the treatment of IgAN, and how this can impact disease pathogenesis.

Jonathan-barratt
Brad-rovin
Wigan
Nephropathy
Proteinuria
Complement-inhibition
B-cell-modulation
Blys-april-targeting

vimarsana © 2020. All Rights Reserved.